C
Clyde E. Markowitz
Researcher at University of Pennsylvania
Publications - 69
Citations - 4289
Clyde E. Markowitz is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Multiple sclerosis & Visual acuity. The author has an hindex of 26, co-authored 66 publications receiving 3666 citations. Previous affiliations of Clyde E. Markowitz include Wake Forest University & Columbia University.
Papers
More filters
Journal ArticleDOI
Relation of Visual Function to Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis
Jennifer B. Fisher,Dina A. Jacobs,Clyde E. Markowitz,Steven L. Galetta,Nicholas J. Volpe,M. Ligia Nano-Schiavi,Monika Baier,Elliot M. Frohman,Heather Winslow,Teresa C. Frohman,Peter A. Calabresi,Maureen G. Maguire,Gary Cutter,Laura J. Balcer +13 more
TL;DR: Scores for low-contrast letter acuity and contrast sensitivity correlate well with RNFL thickness as a structural biomarker, supporting validity for these visual function tests as secondary clinical outcome measures for MS trials.
Journal ArticleDOI
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
Amit Bar-Or,Peter A. Calabresi,Douglas L. Arnold,Clyde E. Markowitz,Stuart Shafer,Lloyd H. Kasper,Emmanuelle Waubant,Suzanne Gazda,Robert J. Fox,Michael Panzara,Neena Sarkar,Sunil Agarwal,Craig H. Smith +12 more
TL;DR: An apparent reduction in relapses was also observed over the 72 weeks compared with the year before therapy, and events were limited to mild‐to‐moderate infusion‐associated events, which tended to decrease with subsequent infusions.
Journal ArticleDOI
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
Jerry S. Wolinsky,Ponnada A. Narayana,Paul O'Connor,P. K. Coyle,Corey C. Ford,Kenneth P. Johnson,Kenneth P. Johnson,Aaron Miller,Aaron Miller,Lillian Pardo,Shaul Kadosh,David Ladkani,Lorne F. Kastrukoff,Pierre Duquette,Mark S. Freedman,Marc Debouverie,Catherine Lubetski,Gilles Edan,E Roullet,Christian Confavreux,Alan J. Thompson,L D Blumhardt,L D Blumhardt,Stanley Hawkins,Thomas F. Scott,Daniel Wynn,Joanna Cooper,Stephen Thurston,Stanton B. Elias,Clyde E. Markowitz,David Mattson,John H. Noseworthy,Elizabeth A. Shuster,Jonathan L. Carter,Fred D. Lublin,WH Stuart,Michael D. Kaufman,Gary Birnbaum,Kottil Rammohan,Ruth H. Whitham,Cornelia Mihai,Steven J. Greenberg,Craig M. Smith,Mark A. Agius,Stan Van Den Noort,Lawrence W. Myers,James G. Nelson,Douglas S. Goodin,Barry G. W. Arnason,Khurram Bashir,Sharon G. Lynch,Patricia K. Coyle,Stephen Kamin,William A. Sheremata,Galen Mitchell,Andrew D. Goodman,Norman J Kachuck,Peter B. Dunne,J. William Lindsey,Elliot M. Frohman,James D. Bowen,Benjamin Rix Brooks,John W. Rose,Harold L. Moses,Douglas Jeffrey,Anne H. Cross,Robert P. Lisak,Timothy Vollmer,Jack P. Antel,Gary Cutter,Luanne M. Metz,Henry F. McFarland,Steven Reingold,Fred D. Lublin,Irina Vainrub,Lucie Lambert,Fengwei Zhong,Jeff Rasmituth,Saria Momin,Rivka Kreitman,Galia Shifroni,Irit Pinchasi,Yafit Stark +82 more
TL;DR: To determine whether glatiramer acetate slows accumulation of disability in primary progressive multiple sclerosis, a new drug is developed that acts as a ‘spatially aggregating agent’ to reduce the risk of disease progression.
Journal ArticleDOI
Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis.
Lauren S. Talman,Esther R. Bisker,David J. Sackel,David A. Long,Kristin M. Galetta,John N. Ratchford,Deacon J. Lile,Sheena K. Farrell,Michael J. Loguidice,Gina Remington,Amy Conger,Teresa C. Frohman,Dina A. Jacobs,Clyde E. Markowitz,Gary Cutter,Gui-Shuang Ying,Yang Dai,Maureen G. Maguire,Steven L. Galetta,Elliot M. Frohman,Peter A. Calabresi,Laura J. Balcer +21 more
TL;DR: Cross‐sectional studies of optical coherence tomography show that retinal nerve fiber layer thickness is reduced in multiple sclerosis (MS) and correlates with visual function, and how longitudinal changes in RNFL thickness relate to visual loss is determined.
Journal ArticleDOI
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.
Sokratis A. Apostolidis,Mihir Kakara,Mark M Painter,Rishi R. Goel,Divij Mathew,Kerry Lenzi,Ayman Rezk,Kristina R. Patterson,Diego A. Espinoza,Jessy C. Kadri,Daniel M. Markowitz,Clyde E. Markowitz,Ina Mexhitaj,Dina A. Jacobs,Allison Babb,Michael R. Betts,Eline T. Luning Prak,Daniela Weiskopf,Alba Grifoni,Kendall A. Lundgreen,Sigrid Gouma,Alessandro Sette,Alessandro Sette,Paul Bates,Scott E. Hensley,Allison R. Greenplate,E. John Wherry,Rui Li,Amit Bar-Or +28 more
TL;DR: In this article, an anti-CD20 monoclonal antibody (aCD20) was used to reduce spike-specific and receptor-binding domain (RBD)-specific antibody and memory B cell responses in most patients.